regulatory compliance across the trial lifecycle—from initial concept through close-out. This article provides an end-to-end process guide tailored for clinical operations, regulatory affairs, and medical affairs professionals working on global clinical trials in the US, UK, and EU. We will explore how clinical trial feasibility integrates with regulatory expectations from the FDA, EMA, and MHRA, and how it supports robust trial design and execution. The discussion includes practical insights on clinical trial site feasibility, the use of feasibility questionnaires in clinical trials, and examples such as the CodeBreak 100 trial to illustrate real-world application.

Understanding Clinical Trial Feasibility: Context and Core Definitions

Clinical trial feasibility refers to the systematic assessment of whether a proposed clinical study can be successfully conducted within the defined parameters, including patient recruitment, site capabilities, regulatory compliance, and resource availability. It is a foundational step in the trial lifecycle that directly impacts study timelines, costs, and data integrity.

Key terms include:

• Clinical Trial Site Feasibility: Evaluation of potential investigational sites’ capacity, experience, patient population, and infrastructure to conduct the trial.
• Feasibility Questionnaire Clinical Trials: Structured tools used to collect standardized information from sites to inform site selection and trial planning.
• Feasibility Study Clinical Trial: A preliminary investigation, often smaller in scale, conducted to assess operational aspects before a pivotal trial.

Feasibility assessments occur early in the trial lifecycle, typically during protocol development and before site initiation. They ensure alignment with scientific objectives and regulatory standards. For instance, the EU Clinical Trials Regulation (EU-CTR) emphasizes the importance of adequate site selection and patient recruitment planning as part of trial authorization.

Regulatory and GCP Expectations in the US, EU, and UK

Regulatory authorities in the US, EU, and UK require sponsors and investigators to conduct thorough feasibility assessments to ensure trial integrity and participant safety. These expectations are embedded within Good Clinical Practice (GCP) guidelines and regional regulations:

1. United States (FDA): The FDA’s 21 CFR Parts 312 and 812, alongside ICH E6 (R2) GCP guidelines, mandate that sponsors verify the suitability of clinical sites and investigators. The FDA expects documentation of feasibility assessments to support trial design and monitoring plans.
2. European Union (EMA/EU-CTR): The EU Clinical Trials Regulation (536/2014) requires sponsors to provide detailed information on site selection and recruitment feasibility in the clinical trial application. EMA guidance recommends using feasibility questionnaires to evaluate sites’ operational capacity and patient availability.
3. United Kingdom (MHRA): Post-Brexit, the MHRA maintains standards aligned with ICH E6 and the UK Clinical Trial Regulations. Sponsors must demonstrate that site feasibility assessments have been conducted to ensure compliance with safety and data quality standards.

Globally recognized frameworks such as ICH E8 (General Considerations for Clinical Trials) and WHO guidelines reinforce the need for feasibility assessments to mitigate risks related to recruitment delays, protocol deviations, and data inconsistencies. Regulatory inspections frequently review feasibility documentation as part of trial oversight.

Practical Design and Operational Considerations for Clinical Trial Feasibility

Implementing clinical trial feasibility requires a structured, stepwise approach integrating scientific, operational, and regulatory inputs. Key considerations include:

1. Protocol Development: Define inclusion/exclusion criteria and endpoints with feasibility in mind. Overly restrictive criteria may limit patient availability, while ambiguous criteria can affect data consistency.
2. Feasibility Questionnaire Clinical Trials: Develop comprehensive questionnaires to capture site capabilities, patient population metrics, prior study experience, staff qualifications, and infrastructure details. Ensure questionnaires are standardized and validated.
3. Site Selection Process: Use feasibility data to rank and select sites. Consider geographic diversity, recruitment potential, and regulatory environment. Engage with sites early to clarify expectations and timelines.
4. Resource Planning: Assess availability of trained personnel, investigational product handling capacity, and data management systems at sites.
5. Risk Assessment: Identify potential recruitment bottlenecks and operational challenges. Develop mitigation strategies such as backup sites or adaptive recruitment plans.

For example, in the CodeBreak 100 trial, a targeted feasibility study was instrumental in identifying sites with appropriate patient populations and experience in oncology trials, enabling efficient enrollment and compliance with FDA and EMA requirements.

Common Pitfalls, Inspection Findings, and How to Avoid Them

Despite its importance, clinical trial feasibility is often a source of regulatory findings and operational challenges. Common pitfalls include:

• Inadequate Site Assessment: Failure to verify site infrastructure or staff qualifications can lead to protocol deviations and data quality issues.
• Overestimation of Recruitment Potential: Sites may over-report patient availability, resulting in enrollment delays and increased costs.
• Poor Documentation: Lack of documented feasibility assessments impairs regulatory inspections and audit readiness.
• Insufficient Training: Site staff unfamiliar with protocol requirements or feasibility tools may compromise trial conduct.

Inspection findings from FDA and EMA audits frequently highlight these issues. To avoid them, teams should implement robust SOPs for feasibility assessments, conduct training on the use of feasibility questionnaires, and establish quality control checks. Metrics such as site activation timelines and recruitment rates should be monitored continuously to identify deviations early.

US vs EU vs UK Nuances and Real-World Case Examples

While the US, EU, and UK share harmonized principles under ICH guidelines, there are nuanced differences in clinical trial feasibility expectations:

• Regulatory Submission Requirements: The EU-CTR requires detailed feasibility data as part of the clinical trial application dossier, whereas the FDA focuses more on sponsor oversight and monitoring plans.
• Site Qualification Processes: The MHRA emphasizes site-specific risk assessments and may request additional documentation during inspections.
• Data Privacy and Patient Access: GDPR in the EU and UK imposes strict limitations on patient data use during feasibility assessments, requiring careful planning of data collection methods.

Case Example 1: A multinational oncology trial faced recruitment delays due to inconsistent feasibility assessments across US and EU sites. Harmonizing feasibility questionnaires and centralizing feasibility data review improved site selection and enrollment rates.

Case Example 2: In a Phase II respiratory study, early engagement with UK sites and adherence to MHRA guidance on feasibility documentation prevented inspection findings related to site qualification.

These examples highlight the importance of understanding regional regulatory nuances and fostering cross-functional collaboration among clinical operations, regulatory affairs, and medical affairs teams.

Implementation Roadmap and Best-Practice Checklist

To operationalize clinical trial feasibility effectively, follow this stepwise roadmap:

1. Define Feasibility Objectives: Align with protocol goals and regulatory requirements.
2. Develop Standardized Feasibility Questionnaires: Incorporate site capability, patient population, and regulatory compliance queries.
3. Identify and Engage Potential Sites: Use databases, investigator networks, and prior trial data.
4. Collect and Analyze Feasibility Data: Evaluate site responses quantitatively and qualitatively.
5. Select Sites Based on Feasibility Scores: Prioritize sites with optimal recruitment potential and compliance history.
6. Document Feasibility Assessments: Maintain records for regulatory submissions and audits.
7. Train Site Staff on Protocol and Feasibility Expectations: Ensure understanding of recruitment targets and data quality standards.
8. Monitor Recruitment and Site Performance: Use metrics to detect deviations and implement corrective actions.
9. Update Feasibility Assessments as Needed: Adapt to evolving trial conditions or regulatory feedback.

Best-Practice Checklist:

• Use validated feasibility questionnaires tailored to study design and region.
• Ensure compliance with FDA, EMA, and MHRA regulations regarding site selection and documentation.
• Integrate feasibility data review into trial governance and risk management processes.
• Provide ongoing training and support to site personnel on feasibility and recruitment strategies.
• Maintain transparent, auditable records of all feasibility activities.
• Leverage technology platforms for centralized feasibility data collection and analysis.

Comparison of Clinical Trial Feasibility Regulatory Expectations: US, EU, and UK

Aspect	United States (FDA)	European Union (EMA/EU-CTR)	United Kingdom (MHRA)
Regulatory Reference	21 CFR Parts 312, ICH E6 (R2)	EU Clinical Trials Regulation (536/2014), ICH E6 (R2)	UK Clinical Trial Regulations, ICH E6 (R2)
Feasibility Documentation	Required for sponsor oversight; inspection focus on site suitability	Mandatory inclusion in trial application; detailed site feasibility data expected	Emphasis on documented site risk assessments and qualification
Data Privacy Considerations	HIPAA compliance; limited patient data in feasibility	GDPR compliance; strict controls on patient data use	GDPR-aligned; additional MHRA guidance on data handling
Inspection Focus	Site qualification, recruitment metrics, documentation	Feasibility data completeness, recruitment planning, site capabilities	Site risk assessments, documentation, and compliance with UK regulations

Key Takeaways for Clinical Trial Teams

• Conduct comprehensive clinical trial feasibility assessments early to ensure site suitability and realistic recruitment projections.
• Align feasibility documentation and processes with FDA, EMA, and MHRA regulatory requirements to minimize inspection risks.
• Implement standardized feasibility questionnaires and maintain thorough records to support trial planning and regulatory submissions.
• Recognize and address regional nuances in feasibility expectations to harmonize multinational trial operations effectively.